Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SAP021 (cannabidiol) is an oral CB1 receptor negative allosteric modulator. It is being evaluated in phase 1 clinical trials for the treatment of neurological diseases.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: SAP021
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
SAP021 is an orally administered cannabinoid. It is under phase 1 clinical development for the treatment of neurological diseases.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: SAP021
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2023
Details:
SAP021 (cannabidiol) is an oral CB1 receptor negative allosteric modulator. It is being evaluated in phase 1 clinical trials for the treatment of neurological diseases.
Lead Product(s): Cannabidiol
Therapeutic Area: Neurology Product Name: SAP021
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2023